Name /bks_53161_deglins_md_disk/bleomycin
02/19/2014 09:11AM
High Alert
bleomycin (blee-oh-mye-sin)
Blenoxane
Classification
Therapeutic: antineoplastics
Pharmacologic: antitumor antibiotics
Pregnancy Category D
Plate # 0-Composite
pg 1 # 1
Adverse Reactions/Side Effects
CNS: aggressive behavior, disorientation, weakness. Resp: PULMONARY FIBROSIS,
pneumonitis. CV: hypotension, peripheral vasoconstriction. GI: anorexia, nausea,
stomatitis, vomiting. Derm: hyperpigmentation, mucocutaneous toxicity, alopecia,
erythema, rashes, urticaria, vesiculation. Hemat: anemia, leukopenia, thrombocytopenia. Local: pain at tumor site, phlebitis at IV site. Metab: weight loss. Misc:
ANAPHYLACTOID REACTIONS, chills, fever.
Interactions
Drug-Drug: Hematologic toxicityqwith concurrent use of radiation therapy
Treatment of: Lymphomas, Squamous cell carcinoma, Testicular embryonal cell carcinoma, Choriocarcinoma, Teratocarcinoma. Intrapleural administration to prevent
the reaccumulation of malignant effusions.
and other antineoplastics. Concurrent use with cisplatinpelimination of bleomycin and mayqtoxicity.qrisk of pulmonary toxicity with other antineoplastics or
thoracic radiation therapy. General anesthesiaqthe risk of pulmonary toxicity.
qrisk of Raynauds phenomenon when used with vinblastine.
Action
Route/Dosage
Indications
Inhibits DNA and RNA synthesis. Therapeutic Effects: Death of rapidly replicating
cells, particularly malignant ones.
Pharmacokinetics
Absorption: Well absorbed from IM and subcut sites. Absorption follows intrapleural and intraperitoneal administration.
Distribution: Widely distributed, concentrates in skin, lungs, peritoneum, kidneys, and lymphatics.
Metabolism and Excretion: 60 70% excreted unchanged by the kidneys.
Half-life: 2 hr (qin renal impairment).
TIME/ACTION PROFILE (tumor response)
ROUTE
ONSET
PEAK
DURATION
IV, IM, Subcut
23 wk
unknown
unknown
Contraindications/Precautions
Contraindicated in: Hypersensitivity; OB, Lactation: Potential for fetal, infant
harm.
Use Cautiously in: Renal impairment (doseprequired if CCr 35 mL/min); Pulmonary impairment; Nonmalignant chronic debilitating illness; Patients with childbearing potential; Geri:qrisk of pulmonary toxicity and reduction in renal function.
Canadian drug name.
Genetic Implication.
Lymphoma patients should receive initial test doses of 2 units or less for the first 2
doses.
IV, IM, Subcut (Adults and Children): 0.25 0.5 unit/kg (10 20 units/m2)
weekly or twice weekly initially. If favorable response, lower maintenance doses given
(1 unit/day or 5 units/wk IM or IV). May also be given as continuous IV infusion at
0.25 unit/kg or 15 units/m2/day for 4 5 days.
Intrapleural (Adults): 15 20 units instilled for 4 hr, then removed.
NURSING IMPLICATIONS
Assessment
Monitor vital signs before and frequently during therapy.
Assess for fever and chills. May occur 3 6 hr after administration and last 4 12
hr.
Monitor for anaphylactic (fever, chills, hypotension, wheezing) and idi-
osyncratic (confusion, hypotension, fever, chills, wheezing) reactions.
Keep resuscitation equipment and medications on hand. Lymphoma patients are
at particular risk for idiosyncratic reactions that may occur immediately or several
hours after therapy, usually after the first or second dose.
Assess respiratory status for dyspnea and rales/crackles. Monitor chest
x-ray before and periodically during therapy. Pulmonary toxicity occurs
primarily in geriatric patients (age 70 or older) who have received 400
CAPITALS indicate life-threatening, underlines indicate most frequent.
Strikethrough Discontinued.
PDF Page #1
Name /bks_53161_deglins_md_disk/bleomycin
02/19/2014 09:11AM
or more units or at lower doses in patients who received other antineoplastics or thoracic radiation. May occur 4 10 wk after therapy. Discontinue and do not resume bleomycin if pulmonary toxicity occurs.
Assess nausea, vomiting, and appetite. Weigh weekly. Modify diet as tolerated. Antiemetics may be given before administration.
Lab Test Considerations: Monitor CBC before and periodically during
therapy. May cause thrombocytopenia and leukopenia (nadir occurs in
12 days and usually returns to pretreatment levels by day 17).
Monitor baseline and periodic renal and hepatic function.
Potential Nursing Diagnoses
Risk for injury (Side Effects)
Disturbed body image (Side Effects)
Implementation
High Alert: Fatalities have occurred with chemotherapeutic agents. Before ad-
pg 2 # 2
Y-Site Compatibility: allopurinol, amifostine, aminocaproic acid, aminophyl-
Plate # 0-Composite
ministering, clarify all ambiguous orders; double-check single, daily, and courseof-therapy dose limits; have second practitioner independently double-check
original order and dose calculations.
Prepare solution in a biologic cabinet. Wear gloves, gown, and mask while handling medication. Discard equipment in specially designated containers.
Lymphoma patients should receive a 1- or 2-unit test dose 2 4 hr before initiation
of therapy. Monitor closely for anaphylactic reaction. May not detect reactors.
Premedication with acetaminophen, corticosteroids, and diphenhydramine may
reduce drug fever and risk of anaphylaxis.
Reconstituted solution is stable for 24 hr at room temperature and for 14 days if
refrigerated.
IM, Subcut: Reconstitute vial with 1 5 mL of sterile water for injection, 0.9%
NaCl, or bacteriostatic water for injection. Do not reconstitute with diluents containing benzyl alcohol when used for neonates.
IV Administration
pH: 4.0 6.0.
Intermittent Infusion: Prepare IV doses by diluting 15-unit vial with at least 5
mL of 0.9% NaCl. Diluent: Further dilute dose in 50 to 1000 mL of D5W or 0.9%
NaCl. Rate: Administer slowly over 10 min.
line, amiodarone, anidulafungin, atracurium, aztreonam, bivalirudin, bumetanide, busulfan, calcium chloride, calcium gluconate, carboplatin, carmustine,
caspofungin, cefepime, chlorpromazine, cimetidine, cisatracurium, cisplatin, codeine, cyclophosphamide, cyclosporine, cytarabine, dacarbazine, dactinomycin,
daptomycin, daunorubicin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doxacurium, doxorubicin, doxorubicin liposome, droperidol, enalaprilat, epinephrine,
epirubicin, ertapenem, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, filgrastim, fludarabine, fluorouracil, fospehnytoin, furosemide, gemcitabine, glycopyrrolate, granisetron, haloperidol, heparin, hetastarch, hydralazine,
hydrocortisone, idarubicin, ifosfamide, insulin, isoproterenol, ketorolac, labetalol, leucovorin calcium, levofloxacin, lidocaine, magnesium sulfate, mannitol,
mechlorethamine, melphalan, meperidine, mesna, metaraminol, methotrexate,
methyldopate, methylprednisolone, metoclopramide, metoprolol, milrinone, mitomycin, mitoxantrone, naloxone, nesiritide, nicardipine, nitroglycerin, norepinephrine, octreotide, ondansetron, oxaliplatin, paclitaxel, palonosetron, pancuronium, pantoprazole, pemetrexed, phentolamine, phenylephrine, piperacillin/
tazobactam, potassium chloride, potassium phosphates, procainamide, quinupristin/dalfopristin, rituximab, sargramostim, sodium acetate, teniposide, thiotepa, tirofiban, trastuzumab, vinblastine, vincristine, vinorelbine, voriconazole.
Y-Site Incompatibility: amphotericin B liposome, dantrolene, phenytoin, tigecycline.
Intrapleural: Dissolve 60 units in 50 100 mL of 0.9% NaCl.
May be administered through thoracotomy tube. Position patient as directed.
Patient/Family Teaching
Instruct patient to notify health care professional if fever, chills, wheezing, faint-
ness, diaphoresis, shortness of breath, prolonged nausea and vomiting, or mouth
sores occur.
Encourage patient not to smoke because this may worsen pulmonary
toxicity.
Explain to the patient that skin toxicity may manifest itself as skin sensitivity, hyperpigmentation (especially at skin folds and points of skin irritation), and skin
rashes and thickening.
Instruct patient to inspect oral mucosa for erythema and ulceration. If ulceration
occurs, advise patient to use sponge brush and rinse mouth with water after eating
and drinking. Opioid analgesics may be required if pain interferes with eating.
2015 F.A. Davis Company
CONTINUED
PDF Page #2
Name /bks_53161_deglins_md_disk/bleomycin
02/19/2014 09:11AM
Plate # 0-Composite
pg 3 # 3
3
PDF Page #3
CONTINUED
bleomycin
Discuss with patient the possibility of hair loss. Explore coping strategies.
Advise patient of the need for contraception during therapy.
Instruct patient not to receive any vaccinations without advice of health care pro-
fessional.
Emphasize need for periodic lab tests to monitor for side effects.
Evaluation/Desired Outcomes
Decrease in tumor size without evidence of hypersensitivity or pulmonary toxicity.
Why was this drug prescribed for your patient?
Canadian drug name.
Genetic Implication.
CAPITALS indicate life-threatening, underlines indicate most frequent.
Strikethrough Discontinued.
